Optimizing laboratory defined macroprolactin algorithm

Introduction Macroprolactinaemia is a well-known analytical problem in diagnostics of hyperprolactinaemia usually detected with polyethylene glycol (PEG) precipitation method. Since there is no harmonization in macroprolactin detection and reporting results, this study proposes and evaluates the usefulness of in-house developed algorithm. The aims were to determine the most suitable way of reporting results after PEG treatment and the possibilities of rationalizing the precipitation procedure. Materials and methods This is a retrospective study based on extracted data for 1136 patients. Prolactin concentrations were measured before and after PEG precipitation on Roche cobas e601. Macroprolactinaemia was defined by percentage recovery and post-PEG prolactin concentrations. Results Prevalence of macroprolactinaemia using recovery criteria of ≤ 40%, ≤ 60%, and post-PEG prolactin concentrations was 3.3%, 8.8% and 7.8%, respectively. Raising the cut-off value from the upper limit of the manufacturer’s reference interval to 32.9 µg/L does not drastically change detected macroprolactinaemia with recovery criteria. Post-PEG prolactin concentrations showed more than half of the patients with macroprolactinaemia would be overlooked. Regardless of the criteria, a cut-off of 47.0 µg/L would miss most of the macroprolactinaemic patients. Repeated recovery measurements of follow-up patients showed there is a significant difference with mean absolute bias of 9%. Conclusions Post-PEG prolactin concentration with corresponding reference interval is the most suitable way of reporting results. All samples with prolactin concentration above the upper limit of the manufacturer’s reference interval should be submitted to PEG precipitation. Follow-up period could be prolonged since the difference between the recoveries of repeated measurements is not clinically significant.

[1]  H. Martin,et al.  Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues. , 2018, The Clinical biochemist. Reviews.

[2]  S. Orešković,et al.  Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. , 2017, Taiwanese journal of obstetrics & gynecology.

[3]  D. Maiter,et al.  Tracking Macroprolactin: Use of an Optimized Polyethylene Glycol Precipitation Method More Compatible with the Requirements and Processes of Automated Core Laboratories. , 2017, The journal of applied laboratory medicine.

[4]  K. Aisaka,et al.  A possible cause of the variable detectability of macroprolactin by different immunoassay systems , 2016, Clinical chemistry and laboratory medicine.

[5]  G. Lippi,et al.  Macroprolactin: searching for a needle in a haystack? , 2016, Clinical chemistry and laboratory medicine.

[6]  C. Ford,et al.  Reference ranges for serum total and monomeric prolactin for the current generation Abbott Architect assay , 2015, Annals of clinical biochemistry.

[7]  A. Šimundić,et al.  Croatian Society of Medical Biochemistry and Laboratory Medicine: national recommendations for venous blood sampling , 2013, Biochemia medica.

[8]  S. Chan,et al.  Importance of screening for macroprolactin in all hyperprolactinaemic sera. , 2013, The Malaysian journal of pathology.

[9]  A. Shimatsu,et al.  Macroprolactinemia: Diagnostic, Clinical, and Pathogenic Significance , 2012, Clinical & developmental immunology.

[10]  K. Veljkovic,et al.  Reporting of post-polyethylene glycol prolactin: precipitation by polyethylene glycol 6000 or polyethylene glycol 8000 will change reference intervals for monomeric prolactin , 2012, Annals of clinical biochemistry.

[11]  Takashi Adachi,et al.  The natural history of macroprolactinaemia. , 2012, European journal of endocrinology.

[12]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[13]  Rahul Gupta,et al.  Macroprolactin; A Frequent Cause of Misdiagnosed Hyperprolactinemia in Clinical Practice , 2010, Journal of Reproduction & Infertility.

[14]  S. Hunter,et al.  Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. , 2010, The Journal of clinical endocrinology and metabolism.

[15]  Thomas P. Smith,et al.  Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. , 2008, Clinical chemistry.

[16]  C. Inagaki,et al.  Development of anti-PRL (prolactin) autoantibodies by homologous PRL in rats: a model for macroprolactinemia. , 2007, Endocrinology.

[17]  J. Gibney,et al.  Specificity and clinical utility of methods for the detection of macroprolactin. , 2004, Clinical chemistry.

[18]  J. Gibney,et al.  Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. , 2003, Clinical chemistry.